Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Alirocumab

Alirocumab shows benefit in SAMS with myotonic dystrophy

Alirocumab shows benefit in SAMS with myotonic dystrophy

There are currently few options for patients with statin intolerance and myotonic dystrophy. In this case report, a 74-year-old male with hypercholesterolaemia (serum LDL cholesterol 210 mg/dL), hypogonadism, insulin-controlled type 2 diabetes mellitus, and minimally elevated serum creatine kinase levels (184 U/L, ref. range 38-174),…

read more »
Alirocumab effective against the spectrum of mutations causative for familial hypercholesterolaemia

Alirocumab effective against the spectrum of mutations causative for familial hypercholesterolaemia

Alirocumab treatment was effective in patients heterozygous for mutations in LDLR, APOB, and PCSK9 genes. This analysis investigated the efficacy of alirocumab in 1191 patients with familial hypercholesterolaemia (FH, inherited high cholesterol) included in 6 trials; 758 were treated with alirocumab. One or more specific…

read more »
ADA 2017: Alirocumab shows benefit in diabetes patients

ADA 2017: Alirocumab shows benefit in diabetes patients

Data from the ODYSSEY trials, including a pooled analysis of nearly 1,000 patients, reported at the American Diabetes Association (ADA) 2017 Scientific Sessions showed that alirocumab was effective in type 1 and 2 diabetes patients, including those with mixed dyslipidaemia, with no impact on HbA1c….

read more »
ODYSSEY APPRISE offers insights into the real world use of PCSK9 inhibitor

ODYSSEY APPRISE offers insights into the real world use of PCSK9 inhibitor

What do we know about patients receiving a PCSK9 inhibitor in real world practice? In the case of alirocumab, what will be the usual dose regimen? These and other questions were the driver for the ODYSSEY APPRISE study, the first European/Canadian study which focused on…

read more »
ODYSSEY KIDS

ODYSSEY KIDS

Alirocumab Study title: : An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia ClinicalTrials.gov Identifier: NCT02890992 Aim To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 8 weeks of treatment…

read more »
ESC Poster news: More reassurance on alirocumab safety at very low LDL cholesterol

ESC Poster news: More reassurance on alirocumab safety at very low LDL cholesterol

30th August 2016, Rome, Italy In an updated safety analysis for alirocumab treatment for up to 104 weeks, there was no evidence of any safety issues affecting neurological or neurocognitive function with alirocumab (1). Data were pooled from 14 Phase II and III trials, comprising…

read more »
ESC Poster news: Alirocumab effective in patients with multiple manifestations of cardiovascular disease

ESC Poster news: Alirocumab effective in patients with multiple manifestations of cardiovascular disease

30th August 2016, Rome, Italy Alirocumab, was effective and well tolerated in patients with multiple manifestations of cardiovascular disease receiving statins with or without other lipid lowering therapy, according to a post hoc analysis of the ODYSSEY trials (1). The investigators evaluated data from patients…

read more »
ODYSSEY JAPAN

ODYSSEY JAPAN

Trial ODYSSEY JAPAN Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy valign=”top”Aim To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable daily statin…

read more »
ODYSSEY JAPAN shows benefit of alirocumab

ODYSSEY JAPAN shows benefit of alirocumab

Alirocumab reduced LDL cholesterol by more than 60% and was well tolerated over 52 weeks in this study in Japanese patients at high cardiovascular risk on statin therapy. This Phase III study included 216 high risk patients, 19% each with heterozygous familial hypercholesterolaemia (FH, inherited…

read more »
ODYSSEY Outcomes

ODYSSEY Outcomes

Alirocumab Safety Alirocumab treatment was well tolerated; injection site reactions occurred in 3.8% of patients in the alirocumab group versus 2.1% on placebo. Trial ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ClinicalTrials.gov Identifier: NCT01663402 Aim To test…

read more »
Alirocumab for Autosomal Recessive Hypercholesterolemia

Alirocumab for Autosomal Recessive Hypercholesterolemia

Results from this in vitro study suggest that PCSK9 inhibition with alirocumab on top of statin treatment may have the potential to lower LDL cholesterol in some patients with autosomal recessive hypercholesterolemia (ARH), a phenocopy of homozygous familial hypercholesterolaemia (FH, inherited high cholesterol). ARH is…

read more »
ODYSSEY ESCAPE

ODYSSEY ESCAPE

Trial Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy (ODYSSEY ESCAPE) Clinical Trials Number: NCT02326220 Aim to evaluate the effect of alirocumab in comparison with placebo on the frequency of LDL apheresis treatments in patients with…

read more »
Positive results with ODYSSEY ESCAPE in severe FH

Positive results with ODYSSEY ESCAPE in severe FH

Topline results from ODYSSEY ESCAPE showed that in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) who required regular lipoprotein apheresis, on top of maximally tolerated lipid lowering therapy, addition of alirocumab significantly reduced the requirement for apheresis. The frequency of apheresis therapy with…

read more »
Benefit of alirocumab in moderate chronic kidney disease

Benefit of alirocumab in moderate chronic kidney disease

Patients with chronic kidney disease (CKD) represent an important high cardiovascular risk group, especially in view of evidence that the prevalence of this condition is increasing rapidly world-wide. Statins with minimal renal excretion are the treatment of choice for management of the associated dyslipidaemia; however,…

read more »
Good news for PCSK9 inhibitors in diabetes patients

Good news for PCSK9 inhibitors in diabetes patients

Findings reported for both evolocumab and alirocumab indicate promise for the PCSK9 inhibitors in patients with diabetes, with similar reductions in low-density lipoprotein (LDL) cholesterol as in nondiabetic patients. For evolocumab, there was also no difference in efficacy between 2-weekly and monthly regimens. A pooled…

read more »
ISA 2015: Alirocumab treatment well accepted by patients and clinicians

ISA 2015: Alirocumab treatment well accepted by patients and clinicians

While injectable treatment is common among some specialities, this is not the case among clinicians managing patients with dyslipidaemia. PCSK9 monoclonal antibody, which is injected subcutaneously every 2 or 4 weeks, is undoubtedly effective in the management of high cardiovascular risk patients with elevated low-density…

read more »
ODYSSEY LONG TERM

ODYSSEY LONG TERM

Trial Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular [CV] Risk Patients With Hypercholesterolemia (ODYSSEY Long Term) Aim To evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk patients with hypercholesterolemia not adequately…

read more »
ODYSSEY CHOICE II

ODYSSEY CHOICE II

Trial Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II) Aim To evaluate the efficacy and safety or alirocumab as add-on to non-statin lipid modifying background therapy (ezetimibe or fenofibrate) or as monotherapy in comparison with…

read more »
ODYSSEY CHOICE I

ODYSSEY CHOICE I

Trial Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) Aim To determine if alirocumab is effective and safe compared with placebo, if used alone or added to…

read more »
ACC 2015 More safety data with PCSK9 inhibitors: patients with very low LDL-C

ACC 2015 More safety data with PCSK9 inhibitors: patients with very low LDL-C

Accumulating data with both alirocumab and evolocumab have so far not indicated specific safety issues. In the latest reports at ACC 2015, there were no safety signals in more than 5,000 patients who achieved very low low-density lipoprotein (LDL) cholesterol levels (<25 or <15 mg/dL)…

read more »